— Know what they know.
Not Investment Advice

AIXC NASDAQ

AIxCrypto Holdings, Inc.
1W: +2.2% 1M: -11.0% 3M: +11.3% YTD: -42.5% 1Y: -63.1% 3Y: -97.2% 5Y: -99.8%
$1.29
-0.09 (-6.52%)
 
Weekly Expected Move ±12.7%
$1 $1 $1 $1 $2
NASDAQ · Healthcare · Medical - Pharmaceuticals · Alpha Radar Neutral · Power 41 · $6.7M mcap · 4M float · 1.56% daily turnover · Short 54% of daily vol
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$6.7M
52W Range0.92-8.81
Volume48,512
Avg Volume60,114
Beta0.52
Dividend
Analyst Ratings
No analyst coverage
Company Info
CEOKevin A. Richardson
Employees4
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2015-06-23
Websiteqlgntx.com
5857 Owens Avenue
Carlsbad, CA 92008
US
760 452 8111
About AIxCrypto Holdings, Inc.

AIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was formerly known as Qualigen Therapeutics, Inc. and changed its name to AIxCrypto Holdings, Inc. in November 2025. The company was founded in 1996 and is based in Carlsbad, California.

Recent Insider Trades

NameTypeSharesPriceDate
FARADAY FUTURE INTEL 0 2025-11-17
FARADAY FUTURE INTEL 978,425 $2.25 2025-11-12
Wang Jiawei 0 2025-09-29

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms